Results 101 to 110 of about 355,053 (311)

Distinct Brain Drivers and Shared Cerebello–Cortical Input in ADCY5 and SGCE Hyperkinetic Movements

Movement Disorders, EarlyView.
Resting‐state fMRI and effective connectivity revealed distinct cerebellar–basal ganglia–cortical interactions in ADCY5 (MxMD‐ADCY5) and SGCE (MYC/DYT‐SGCE) related movement disorders. The cerebellum modulated cortex directly in MYC/DYT‐SGCE, but indirectly via basal ganglia‐cerebellar projections in MxMD‐ADCY5, which also showed reduced subthalamic ...
Clément Tarrano, Cécile Galléa, Asya Ekmen, Cécile Delorme, Eavan M. McGovern, Quentin Salardaine, Lina Daghsen, Manon Gomes, Vanessa Brochard, Eoin Mulroy, Kailash P. Bhatia, Carlo Fusco, Miryam Carecchio, Norbert Brüggemann, Alexander Münchau, Victoria Gonzalez, Diane Doummar, Christine Tranchant, Mathieu Anheim, Philippe Damier, Florence Riant, Mohamed Doulazmi, Agathe Roubertie, Caroline Dubacq, Oriane Trouillard, Romain Valabregue, Mélanie Didier, Benoit Beranger, Pierre Pouget, Marie Vidailhet, Sabine Meunier, Aurélie Méneret, Yulia Worbe, Emmanuel Roze   +33 more
wiley   +1 more source

Real-world use of botulinum toxin-A for post-stroke spasticity in the Netherlands: a retrospective claims study

Journal of Rehabilitation Medicine
Objective: The aim of this observational study was to describe the real-world use of botulinum toxin-A in patients with a stroke in the Netherlands. Methods: This study used longitudinal insurance claims data between 2012 and 2016 with 30% nationwide ...
Max van Wijk, Mary Verhoeven, Thom S. Lysen, Hanne van Ballegooijen, Alexander C.H. Geurts   +4 more
doaj   +1 more source

The Effect of Different Doses of Botulinum Toxin on Masseter Muscle in Patients with Bruxism.

Erbil Dental Journal, 2022
Background and Objectives: Botulinum toxin type A is produced by clostridium botulinum. It acts by inhibiting the release of acetylcholine from cholinergic neurons.
Kawa F. Dizaye, Sarezh Jamal Jalal
doaj  

Driving Cerebellar Theta Oscillations Interferes With Voluntary Neck Movements in Cervical Dystonia

Movement Disorders, EarlyView.
Abstract Background Cervical dystonia (CD) is a movement disorder with a complex pathophysiology, including cerebellar abnormalities. Transcranial alternating current stimulation (tACS), a noninvasive neuromodulation technique capable of entraining brain oscillations, can transiently modulate neuronal activity and enhance resonant rhythms.
Davide Costa, Andrea Guerra, Daniele Birreci, Massimiliano Passaretti, Martina De Riggi, Anna Sofia Grandolfo, Valentina D'Onofrio, Luca Angelini, Giulia Paparella, Matteo Bologna   +9 more
wiley   +1 more source

Phenotyping Overactive Bladder – Part 2: Can Management be Improved by Phenotyping, and Targeting Therapy According to Urgency Type and Other Characteristics? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 904-913, June 2026.
ABSTRACT Introduction Management of overactive bladder (OAB) has a stepwise approach in adults and children. This does not account for individual patient variations, which may explain suboptimal outcomes in many patients. Distinct OAB profiles, based on patient characteristics, symptoms, urodynamic findings and imaging have been discussed in Part 1 ...
Michel Wyndaele, Michael Samarinas, Apostolos Apostolidis, D. Carolina Ochoa, Giovanni Mosiello, Brigitte Schurch, Pradeep Tyagi, Alan Wein, Paul Abrams, John E. Speich   +9 more
wiley   +1 more source

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Should We Consider Sacral Nerve Stimulation as a Treatment for Neurogenic Lower Urinary Tract Dysfunction? ICI‐RS 2025

Neurourology and Urodynamics, Volume 45, Issue 5, Page 945-950, June 2026.
ABSTRACT Aims To explore the boundary of clinical use of sacral nerve stimulation (SNS) in neurogenic lower urinary tract dysfunction (NLUTD), identifying barriers to approval and early‐impact research questions. Methods This review is derived from a proposal discussion at the International Consultation on Incontinence‐Research Society in Bristol in ...
Marcus J. Drake, Mathijs de Rijk, Stefania Musco, Jalesh Panicker, Michał Późniak, Nikita Bhatt, Brigitte Schurch   +6 more
wiley   +1 more source

Cosmetic use of botulinum toxin type A in the elderly

Clinical Interventions in Aging, 2007
Christine M ChengDepartment of Clinical Pharmacy, University of California, San Francisco, CA, USAAbstract: Botulinum toxin type A injections are one of the most popular cosmetic procedures for diminishing the appearance of facial lines caused by ...
Christine M Cheng
doaj  

From Toxin to Treatment: A Narrative Review on the Use of Botulinum Toxin for Autonomic Dysfunction

Toxins
Since its regulatory approval over a half-century ago, botulinum toxin has evolved from one of the most potent neurotoxins known to becoming routinely adopted in clinical practice.
Lucas Rempel, Raza N. Malik, Claire Shackleton, Martín Calderón-Juárez, Rahul Sachdeva, Andrei V. Krassioukov   +5 more
doaj   +1 more source

Expanding the Phenotype of PARK‐PRKN to Spastic Paraplegia: A Report of Two Cases

Movement Disorders Clinical Practice, EarlyView.
Nicolas Geoffre, Thomas Ollivier, Guillaume Baille, Luc Defebvre, Vincent Huin, Eugenie Mutez   +5 more
wiley   +1 more source